Values as of: 2025-01-22
COMMON STOCK | Biotechnology |
Last Closing
USD 28.44Change
-0.71 (-2.44)%Market Cap
USD 17.71BVolume
770.00Analyst Target
N/AVerdict
Verdict
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company Website : https://www.royaltypharma.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| CSJ:F | CSL Limited |
-1.52 (-0.93%) |
USD 82.25B |
| CSJA:F | CSL LTD SPON.ADR 2 |
-0.50 (-0.62%) |
USD 80.37B |
| RGO:F | Regeneron Pharmaceuticals Inc |
+10.80 (+1.66%) |
USD 74.00B |
| UNC0:F | UCB S.A. UNSP.ADR 1/2 |
+0.50 (+0.56%) |
USD 36.29B |
| 1AE:F | Argen-X |
-9.20 (-1.45%) |
USD 36.18B |
| 1AEA:F | argenx SE |
-10.00 (-1.60%) |
USD 36.18B |
| DUL:F | Alnylam Pharmaceuticals Inc |
+16.90 (+7.18%) |
USD 29.18B |
| 22UA:F | BioNTech SE |
+2.20 (+2.06%) |
USD 26.21B |
| 49B:F | BeiGene Ltd. |
-0.10 (-0.64%) |
USD 20.08B |
| 49BA:F | BeiGene Ltd |
-2.00 (-0.96%) |
USD 18.99B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 16.65% | 84% | B | 92% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 16.65% | 84% | B | 92% | A | ||
| Trailing 12 Months | |||||||
| Capital Gain | 6.68% | 63% | D | 53% | F | ||
| Dividend Return | 3.15% | 57% | F | 32% | F | ||
| Total Return | 9.83% | 63% | D | 48% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -5.27% | 50% | F | 28% | F | ||
| Dividend Return | -4.20% | 51% | F | 27% | F | ||
| Total Return | 1.06% | 50% | F | 35% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 7.54% | 100% | F | 95% | A | ||
| Risk Adjusted Return | -55.76% | 34% | F | 17% | F | ||
| Market Capitalization | 17.71B | 98% | N/A | 90% | A- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
